CIZZLE BIOTECHNOLOGY HOLDINGS PLC

Management Reports • Apr 14, 2025

National Storage Mechanism | Additional information

RNS Number : 8834E

Cizzle Biotechnology Holdings PLC

14 April 2025

REACH

14 April 2025

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Launch of New Website

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce that it has launched its new corporate website, which can be viewed at :

https://cizzlebiotechnology.com

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"I am delighted to announce that our new website is now live for all stakeholders including shareholders, investors and customers, to access a wide range of information and latest news on the Company's status and products. This is an exciting time for Cizzle Biotechnology as we continue to finalise our near term regulatory and launch plans in the USA as part of our global strategy to bring the non-invasive, cost effective, CIZ1B Biomarker test for early-stage lung cancer to market.  The new website is designed to provide a user-friendly interface for all stakeholders and we look forward to adding new content as part of an enhanced communication strategy to support the Company's growth."

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	+44(0) 20 3328 5656
John Depasquale/Piers Shimwell (Corporate Finance)
Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

IFC Advisory Limited		+44(0) 20 3934 6630
Tim Metcalfe
Florence Chandler

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered into commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.  Cizzle was admitted to trading on the Main Market of the London Stock Exchange in May 2021. 

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUSVWRVOUSARR